Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Romosozumab Among Latest Drugs Up For CHMP Opinion

Executive Summary

Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.
Advertisement

Related Content

UK Pilot To Generate Real World Data On Medicinal Cannabis Use
UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research
French To Launch Two-Year Medicinal Cannabis Pilot Project
UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research
PTC To Fight EMA Translarna No, Novartis Considers Revolade Next Steps
Amgen/UCB To Appeal EMA’s 'Over Cautious' Evenity Rejection
Emmaus and Mitsubishi Tanabe Refuse To Take EU Approval Blows Quietly
Companies Keep The Faith As New Products Await EMA Verdict
GW Pharma Looks Forward To EU Epidyolex Launch
Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel